It's an incurable cancer? Well bugger that!
In the long human struggle against cancer, few moments carry the weight of a scientist choosing to become his own experiment. Richard Scolyer, an Australian pathologist who helped transform melanoma from a near-certain death into a survivable disease, faced a glioblastoma diagnosis in 2023 and refused the standard trajectory — instead undergoing a world-first combination of immunotherapy and a personalized vaccine before surgery, a protocol he and colleague Georgina Long had pioneered in melanoma. He died three years later, at fifty-nine, leaving behind a family, a clinical trial, and the rare example of a researcher who answered his own question with his own life.
- Glioblastoma kills most patients within a year, and two decades of standard treatment had done almost nothing to change that — Scolyer knew the odds and chose to challenge them anyway.
- With no approved path forward, Scolyer and Long adapted their melanoma immunotherapy breakthroughs in real time, designing a personalized treatment for a disease it had never been tested against.
- The emotional weight was immense: Long moved from grief to planning within hours of her friend's diagnosis, and Scolyer documented his physical and cognitive decline publicly, refusing to soften the reality for anyone watching.
- Early scans showed a positive immune response in his brain — fragile evidence, but enough to launch a small clinical trial attempting to replicate what his case had demonstrated.
- Scolyer died three years after diagnosis, but the trial he seeded continues, carrying forward the possibility that his willingness to be both scientist and subject may yet save lives he never lived to see.
Richard Scolyer had spent his career turning melanoma from a near-certain death sentence into something survivable — he and colleague Georgina Long had pushed global cure rates from under ten percent to roughly fifty, work that earned them joint recognition as Australian of the Year in 2024. Then, in 2023, Scolyer was diagnosed with glioblastoma, an aggressive brain tumour that kills most patients within a year. Standard treatment had barely changed in two decades. He decided not to accept it.
What he and Long had learned from melanoma was that combining immunotherapy drugs and administering them before surgery — rather than after — produced better results, and that a vaccine tailored to a tumour's specific mutations could sharpen the immune system's response further. No one had tried this on a brain tumour patient. Scolyer volunteered to go first, with Long, his closest collaborator, helping to design and carry out the treatment.
The scans that followed were cautiously encouraging. The immune response appeared positive — not a cure, but a signal. That was enough to justify a small clinical trial, now underway, attempting to replicate what Scolyer's case had shown. He documented his treatment openly throughout, sharing the physical and cognitive toll without softening it, and in a final letter released after his death, he urged scientists to stay brave and governments to keep funding the research that makes breakthroughs possible.
Scolyer died three years after his diagnosis, at fifty-nine, survived by his wife Katie Nicholl and their three children. Prime Minister Anthony Albanese called him one of Australia's brightest lights. The clinical work he made possible continues — built on the foundation of a man who chose to be both the question and the answer.
Richard Scolyer was fifty-nine when he decided to become the first human test case for his own untested idea. The Australian pathologist had spent his career studying melanoma alongside his colleague Georgina Long, work that had quietly transformed what was once a near-certain death sentence into something manageable—half of advanced melanoma patients now survive, up from fewer than one in ten. Then, in 2023, Scolyer himself was diagnosed with glioblastoma, an aggressive brain tumour that kills most patients within a year. The standard treatment—surgery, radiation, chemotherapy—had barely evolved in twenty years. He decided he would not accept that trajectory.
What Scolyer and Long had learned from melanoma was that immunotherapy, which trains the body's own immune system to recognize and attack cancer cells, worked better when multiple drugs were combined and given before surgery rather than after. They had also developed a vaccine tailored to the specific mutations in a patient's tumour, sharpening the immune system's ability to hunt down cancer. No one had ever tried this approach on a brain tumour patient. Scolyer volunteered to be the first.
Long spent the hours after learning of her friend's diagnosis moving through grief and then into planning. She knew the odds of a cure were remote. But she also knew that doing nothing meant accepting a timeline measured in months. In 2023, Scolyer underwent combination pre-surgery immunotherapy followed by his personalized vaccine—a medical experiment conducted by a scientist on himself, with his closest collaborator holding the instruments.
The scans that followed suggested something was working. The immune response in his brain appeared positive. That signal, however fragile, was enough to justify moving forward. A small clinical trial began, attempting to replicate what had happened in Scolyer's case. The experiment was not a cure—Scolyer died three years after his diagnosis, his wife Katie Nicholl and three children at his side—but it was a beginning. His case demonstrated that the boundary between researcher and subject could be crossed, that a scientist could choose to be both the question and the answer.
Scolyer documented his treatment publicly, sharing the physical and cognitive toll without softening the reality. In his final letter, released after his death, he wrote that he had wanted to keep contributing even in his darkest hours. He thanked Australians for laughing with him and crying with him, for allowing him to share his journey "warts and all." He called on scientists to remain brave and inquisitive, and on governments to fund the innovations that push cancer research forward. Prime Minister Anthony Albanese called him "one of our brightest lights and one of our biggest hearts," a man who took the nation into his confidence and lifted everyone in the process.
Scolyer and Long had been named Australian of the Year together in 2024, recognition of their melanoma work that had saved countless lives across the globe. That same year, Scolyer was already dying from the disease he had chosen to fight with an experiment no one had attempted before. His death does not erase what the trial might yet reveal. The clinical work continues, built on the foundation of his willingness to be both scientist and patient, to refuse the certainty of decline and instead offer himself as evidence that another path might exist.
Citações Notáveis
I wanted to keep contributing, even in my darkest hour— Richard Scolyer, in his final letter
One of our brightest lights and one of our biggest hearts— Prime Minister Anthony Albanese, on Scolyer
A Conversa do Hearth Outra perspectiva sobre a história
Why did Scolyer choose to undergo an experimental treatment rather than the standard protocol?
Because the standard protocol—surgery, radiation, chemotherapy—hasn't changed meaningfully in two decades, and it fails most patients within a year. He and Long had just spent years proving that a different approach worked for melanoma. He couldn't accept that brain cancer had to be a death sentence.
Was Long hesitant to treat her friend?
She grieved first, then got to work. She knew the odds were minuscule, but she also knew what she and Scolyer had learned about sequencing and combination therapy. The question wasn't whether it would cure him—they both understood that was unlikely. It was whether it might give him more time, and whether it might teach something that could help others.
What made this treatment different from what they'd tried before?
They used multiple immunotherapy drugs together, before surgery rather than after. They also created a vaccine personalized to his tumour's genetic signature. It was melanoma logic applied to the brain for the first time.
Did it work?
The scans showed a positive immune response. That's not a cure, but it was enough to justify starting a clinical trial. Scolyer lived three years after diagnosis—longer than most glioblastoma patients, though not long enough.
What did he leave behind?
A documented journey that refused to hide the difficulty. A clinical trial that's still running. And a demonstration that sometimes the most important research happens when the researcher becomes the subject, when someone decides the risk of trying is better than the certainty of waiting.